Article
Series of studies explore safety and efficacy of anti-VEGF monoclonal antibody treatment for exudative AMD
Two Phase III studies are now underway evaluating ranibizumab (formerlyrhu Fab V2, Lucentis; Genentech) for the treatment of exudative age-relatedmacular degeneration (AMD). The studies are based on Phase I/II study results,demonstrating it is well tolerated and offers promising biological and clinicalactivity, said Jeffrey S. Heier, MD.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
